Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.47 |
| ▸ | CDK4 | P11802 | 6/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700312 | 0.88 | HDAC1 (0.51) | CDK2CDK4CCNE1HDAC1IGF1R | |
| SCHEMBL701105 | 0.87 | CDK2 (0.45) | CDK2CDK4CCNE1SYKHDAC1 | |
| SCHEMBL699362 | 0.85 | CDK2 (0.43) | CDK2CDK4CCNE1SYKIGF1R | |
| SCHEMBL699170 | 0.84 | CDK2 (0.50) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL702195 | 0.84 | CDK2 (0.62) | CDK2CDK4CCNE1HDAC1CDK1 | |
| SCHEMBL701093 | 0.81 | IGF1R (0.42) | CDK2CDK4CCNE1SYKIGF1R | |
| SCHEMBL700180 | 0.79 | CDK2 (0.49) | CDK2CDK4CCNE1SYKHDAC1 | |
| SCHEMBL7977441 | 0.79 | CDK2 (0.54) | CDK2CDK4CCNE1CDK1 | |
| SCHEMBL7977540 | 0.76 | CDK2 (0.49) | CDK2CDK4CCNE1SYKHDAC1 | |
| SCHEMBL701720 | 0.75 | HDAC1 (0.55) | CDK2CDK4CCNE1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | CDK2 16/4885CDK4 15/4885CCNE1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.